ATrial Tachycardia PAcing Therapy in Congenital Heart

Launched by IAN LAW · Jul 3, 2017

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a special type of pacemaker, called an atrial anti-tachycardia device (ATD), for patients with congenital heart disease (CHD) who have a specific heart rhythm problem known as intra-atrial re-entrant tachycardia (IART). The researchers want to find out if this device can help manage arrhythmias—irregular heartbeats—especially as patients with CHD age and experience more heart issues. They will gather information from patients' health records and follow them over time to see how well the ATD works and what programming settings might be most effective.

To participate in this trial, patients need to have congenital heart disease, be diagnosed with an atrial arrhythmia, and have an ATD implanted with its anti-tachycardia feature turned on. The study is open to patients of all ages and genders. Participants can expect to provide their medical history and attend follow-up appointments to see how the device is performing. This research is important because it can help improve treatment options for many individuals with congenital heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • must have structural CHD, an atrial arrhythmia and an ATD implanted. ATP must be turned on.
• Exclusion Criteria:
• • Other arrhythmias substrates such as Long QT (LQT), hypertrophic Cardiomyopathy (HCM), Catecholaminergic polymorphic ventricular tachycardia (CPVT), Arrhythmogenic Right Ventricular Cardiomyopathy.(ARVC), Brugada \& patients who undergo transplant, surgical maze, or ablation within 5 years of ATD implantation.